军队干休所稳定期慢性阻塞性肺疾病患者情况调查

Investigations of chronic obstructive pulmonary disease patients in stable stage in military retired cadres

目的 探索2007年1月-2011年12月5家北京军队干休所160例慢性阻塞性肺病（COPD）患者的一般情况及药物使用情况。方法 收集5家北京军队干休所诊断为COPD的患者,根据2011年COPD全球倡议修订版规定的改良英国医学研究委员会呼吸困难量表（mMRC）设计的调查表及自制调查表进行统计。结果 患者高龄,合并疾病多,发病平均年龄（69.4±6.5）岁,平均COPD病程（10.1±8.3）年,该组COPD患者综合评估：A低风险24例（15.0%）,B低风险64例（40.0%）,C高风险50例（31.2%）,D高风险22例（13.8%）。占比例较高的是联合用药,单药治疗最常见的是吸入糖皮质激素/长效β2激动剂（ICS/LABA）,占29例（18.1%）。在联合用药当中,是以ICS/LABA为基础的联合用药,包括联用茶碱,长效抗胆碱能药物（LAMA）,磷酸二酯酶4（PDE-4）抑制药。结论 患者对COPD的认知程度有限,治疗比较规范,高风险人群比例较高,以ICS/LABA为主的联合治疗是该组COPD稳定期患者的主要用药。

Objective To investigate the general condition and drug therapy in patients with 160 chronic obstructive pul- monary disease （COPD） patients from 5 military retired cadres in Beijing during January 2007 to December 2011. Methods We col- lected the list of patients who were diagnosed as COPD from prespecified 5 Beijing military retired cadres. Statics analysis was at the basis of modified British medical research council dyspnea scale （mMRC） from The Global Initiative for Chronic Obstructive Lung Disease （GOLD） revised edition 2011 and self-designed questionnaire. Results The patients in this group were in aged and suffered more comobiditis. The average age was （69.4 ±6.5） years old and the course of COPD was （10.1 ±8.3 ） years long. Comprehensive evaluation of COPD in this group was as follows：group A was low risk （15.0%,24/160）, group B was low risk （40.0%,64/160）,group C was high risk （31.2%,50/160,） and group D was high risk （13.8%,22/160）. A higher proportion of drug therapy was drug combination therapy. The most common single drug treatment was inhaled corticosteroid/long-acting beta-agonist （ICS/LABA）,which was 18.1% （29/160）. ICS/LABA based drug combination therapy were the most popular methods,which was including the combination of theophylline,long-acting M-cholinergic receptor antagonist and phosphodiesterase type 4 inhibitor. Conclusion The cognition degree of COPD is limited in this group. However treatments were relatively reasonable. The higher proportion patients are in high risk group and the ICS/LABA based drug combination therapy is the most common drug therapy in this group of patients of stable COPD.